Preliminary Final Report

The results for Anatara Lifesciences Limited for the year ended 30 June 2015 are as follows:

Please click here to view the ASX announcement.

Cleansing Notice and Appendix 3B

Appendix 3B

Anatara Lifesciences has today released a Cleansing Notice – Placement and an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Anatara Forges Industry & Research Alliance with Pork CRC

Anatara Lifesciences is pleased to announce it has signed a Commercial Collaboration Agreement with the Pork Cooperative Research Centre (Pork CRC). The CRC will provide Anatara with services to locate key clinical trial sites and ongoing test sites, assist with the APVMA approval of its lead therapy, DetachTM, and promote the results of these trials.

Please click here to view the ASX announcement.

Anatara General Meeting Results

Anatara Lifesciences is pleased to announce the following results from the General Meeting held on 10th August 2015.

At today’s General Meeting all Resolutions put to Shareholders were passed unanimously on a show of hands.

Please click here to view the ASX announcement.

Appendix 3B

Appendix 3B

Anatara Lifesciences has today released an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Appendix 4C – 4th Quarter

Appendix 4C Financial Report

Anatara Lifesciences has released its Appendix 4C Financial Report, for the 4th quarter ended 30 June 2015, to the market today.

Please click here to view the ASX announcement.

Anatara closes heavily subscribed Share Purchase Plan (SPP)

Anatara Lifesciences is pleased to announce it has raised $2million through a significantly subscribed Share Purchase Plan.

Please click here to view the ASX announcement.

Notice of General Meeting

Anatara Lifesciences has today released a Notice of General Meeting – to be held on Monday 10th August 2015 at 11am at McCullough Robertson, Level 11, 66 Eagle Street, Brisbane.

Please click here to view the ASX announcement.

Appendix 3B

Anatara Lifesciences has today released an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Placement Cleansing Notice

Anatara Lifesciences has today released a Cleansing Notice – Placement.

Please click here to read the ASX Announcement.

Notice of Despatch of Share Purchase Plan Offer Materials

Anatara Lifesciences has released a Notice of despatch of share purchase plan offer materials.

Please click here to read the ASX Announcement

Anatara raises $7million, launches Share Purchase Plan to speed development of Detach™.

Anatara raises $7million, launches Share Purchase Plan to speed development of Detach™.

Please click here to read the ASX announcement.

Successful Capital Raising

Anatara Lifesciences Limited announces that it has completed a first tranche placement of approximately 5.64 million shares to institutional and sophisticated investors at an issue price of $0.78 per share to raise $4.4 million.

Please click here to view the ASX announcement.

Cleansing Notice – Share purchase plan

Anatara will make offers to issue ordinary shares under a share purchase plan.

Please click here to view the ASX Announcement.

Anatara Lifesciences Ltd – Trading Halt

The securities of Anatara Lifesciences have been placed in a trading halt, at the request of the company, pending the release of an announcement.

Please click here to view the ASX Announcement.

Anatara Commences Second Detach™ Trial

Anatara Lifesciences is pleased to announce it has begun its second pivotal field trial of its lead product Detach™, a non-antibiotic, natural therapy to prevent and treat diarrhoea in weaned pigs.

Please click here to view the ASX announcement.

Investor Update – Positive News Flow

Anatara Lifesciences has released its latest investor update to the Australian Securities Exchange.

Please click here to view the ASX announcement.

Appendix 3B

Anatara Lifesciences has released its Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Release of Shares from Mandatory and Voluntary Escrow

Anatara Lifesciences is pleased to announce that in accordance with Listing Rule 3.10A, Anatara Lifesciences advises that 8,170,000 fully paid ordinary shares will be released from escrow on Friday 8 May 2015.

Please click here to view the ASX announcement.

Appendix 4C Interim Financial Report

Anatara Lifesciences has released its Appendix 4C Interim Financial Report, for the 3rd quarter ended 31 March 2015, to the market today.

Please click here to view the ASX announcement.

Anatara Investor Update – Milestone Progress

Anatara has released its latest investor presentation to the Australian Securities Exchange.

Please click here to view the presentation.

Anatara Strengthens Board and Executive Team

Anatara Lifesciences is pleased to announce the appointment of two new members to its executive management team, and strengthens the board with a new non-executive director.

Please click here to view the announcement.

Appendix 4D Interim Financial Report

Anatara Lifesciences has released its Appendix 4D Interim Financial Report, for the Half Year ended 31 December 2014, to the market today.

Please click here to view the ASX announcement.

Anatara Reports Successful Detach™ Trial Results

Anatara Lifesciences is pleased to announce positive results from the first Australian field trial of its lead product Detach™, a non-antibiotic natural product to prevent and treat diarrhoea in piglets.

Please click here to view the announcement.

Anatara begins field trials of Detach™ to support registration

Anatara Lifesciences is pleased to announce it has begun the first pivotal field trial of its lead product Detach™, a non-antibiotic, natural product to prevent and treat diarrhoea in piglets.

Please click here to view the announcement.

Anatara investor presentation

Anatara has released its latest investor presentation to the Australian Securities Exchange.

Please click here to view the presentation.

Anatara Lifesciences welcomes Antibiotic Awareness Week

BRISBANE, November 19, 2014: Anatara Lifesciences, a company developing non-antibiotic treatments for gastrointestinal diseases in animals and humans, has welcomed Antibiotic Awareness Week in Australia to increase awareness around the threat to human health of antibiotic resistance.

Antibiotic Awareness Week is part of a global initiative to raise awareness about antibiotic resistance and promote the responsible use of antibiotics. It urges that the “miracle” of antibiotics be preserved and warns that “no action today, no cure tomorrow”.

Overuse of antibiotics in humans and animals has led to bacteria developing resistance to medicines and becoming so-called “super bugs” that make illnesses harder to treat.

Around 80% of antibiotics in the US are used in animal production.

Anatara Lifesciences has developed a non-antibiotic therapy for diarrhoea called DetachTM that will help reduce the use of antibiotics in pigs.

“Antimicrobial resistance is a threat to human health that is increasingly becoming a major issue for authorities,” Anatara Chairman Mel Bridges said.

“Awareness is growing and with that will come demands from consumers, health authorities and farmers for non-antibiotic therapies for production animals.”

Detach works by stopping bacteria from attaching to the lining of the intestine, as well as blocking the action of their toxins, the underlying cause of diarrhoea. It works differently to antibiotics in that it doesn’t try to kill bacteria and instead lets them pass through the intestine harmlessly.

The Australian Commission on Safety and Quality in Health Care is working with key partners from human health, animal health and agriculture to raise awareness about the problem of antibiotic resistance.

Antibiotic Awareness Week is from November 17 to November 23.

Anatara features on Financial Review Sunday program

Anatara has featured on one of Australia’s leading business television programs, Financial Review Sunday.

The program was about companies listing on the Australian Securities Exchange (ASX) in 2014 and included an interview with Anatara’s chief scientific officer and co-founder Dr Tracey Mynott.

Dr Mynott explained how stringent regulatory requirements necessary to list on the ASX validates the company and provides confidence to potential overseas partners.

To watch the video click here.

 

Anatara newsletter

Anatara has released its first newsletter after successfully listing on the Australian Securities Exchange.

Please click here to view the newsletter.

Anatara manufacturing, clinical trial and European SME status update

Anatara Lifesciences is pleased to announce it has completed its first pilot manufacturing runs of Detach™ and will now initiate manufacture required for registration purposes under the Australian Pesticides and Veterinary Medicines Authority’s (AVPMA’s) product registration approval process.

Please click here to view the announcement.

ASX confirms Anatara admission to Official List

Anatara Lifesciences has been added to the ASX’s Official List and it’s shares are due to commence trading on Thursday, October 16, 2014.

For more read here.

Media Release – Anatara Lifesciences raises $7 million in oversubscribed offer

BRISBANE, 7 October 2014: Anatara Lifesciences is pleased to announce it has raised $7 million through an oversubscribed Initial Public Offering that has now closed.

The company, which is developing non-antibiotic medicines for the treatment and prevention of diarrhoea in animals and humans, offered 14 million shares at $0.50 a share.

Anatara expects the shares to begin trading on the Australian Securities Exchange the week beginning October 13th, with the company opening with a market capitalisation of $18,875,000. The assigned ASX code is ANR.

“The response by investors to the offering has been fantastic,” Anatara Chairman and Co-Founder Dr Mel Bridges said.

“We look forward to delivering on the enthusiasm and faith investors have shown in supporting the company and its planned future. The fact that the lead compound is derived from pineapple stems, a natural and safe resource, and addresses a significant area of unmet medical need, seems to have resonated with investors,” Dr Bridges added.

Anatara’s lead product, DetachTM, is a non-antibiotic therapy to treat and prevent diarrhoea. The company is focused on commercialising DetachTM initially for use in pigs, ahead of expanding its use to other livestock, and then developing it for use in humans.

Health authorities around the world are moving to limit the use of antibiotics in animal production as their overuse contributes to the rise of antibiotic-resistant bacteria, so-called superbugs that threaten human health.

Anatara’s objectives include:

  • Registration of DetachTM for use in pigs in Australia and the European Union
  • Registration of DetachTM for use in pigs in the United States
  • Development of DetachTM for humans

The IPO was led by Wilson HTM with co-manager Peloton Capital and legal advisers McCullough Robertson.

 

Anatara’s share market listing in the news

Anatara’s Chairman Mel Bridges conducted an interview recently with the Australian Associated Press which published an article that was widely reproduced across many media outlets.

The article highlighted that Anatara was raising $7 million in an initial public offering and would list on the Australian Securities Exchange.

It noted that Anatara’s lead product, DetachTM is a non-antibiotic medicine made from an extract from pineapple roots to treat and prevent diarrhoea in food production animals and planned to be first used in pigs.

The article was published on numerous widely-read news websites including The Australian, The Age, The Sydney Morning Herald, The Herald Sun, and The Daily Telegraph.

Anatara seeking partners

By Dylan Bushell-Embling, Australian Life Scientist

Anatara Lifesciences used this week’s BIO International Convention to pursue distribution and development partners for Detach, its new non-antibiotic treatment for diarrhoea.

The company is pursuing commercialisation for the product in pigs first and subsequently plans to expand its use to other livestock and develop the treatment for use in humans.

Detach works by stopping bacteria from attaching to the lining of the intestine, as well as blocking the action of their toxins.

Anatara CEO Dr David Venables said there is a strong market opportunity for Detach in light of growing consumer demand for antibiotic-free food and concerns over antibiotic-resistant “superbugs”.

“The World Health Organization has warned that antimicrobial resistance is a significant looming threat to human health and authorities are now moving to tackle the issue by limiting the use of antibiotics in animal agriculture,” he said.

The article can be found here.

Anatara Lifesciences introduces DetachTM at BIO International Convention

BRISBANE, June 24, 2014: Anatara Lifesciences, a company developing non-antibiotic treatments for gastrointestinal diseases in animals and humans, will be seeking distribution and development partners at the world’s largest biotechnology conference in the United States this week.

The company will be presenting at the 2014 BIO International Convention in San Diego and introducing to thousands of attendees its lead product Detach™, a non-antibiotic treatment for diarrhoea.

Anatara CEO Dr David Venables says the company is addressing a significant global problem around the rise of antimicrobial resistance and so-called “superbugs” caused by the overuse of antibiotics in production animals and humans.

“The World Health Organization has warned that antimicrobial resistance is a significant looming threat to human health and authorities are now moving to tackle the issue by limiting the use of antibiotics in animal agriculture,” Dr Venables says.

Anatara, which raised $1.75 million in a private placing earlier this year, is currently focused on commercialising Detach™ for use in pigs ahead of expanding its use to other livestock and then developing it for use in humans.

“Detach™ is a proven, natural treatment for diarrhoea in piglets and is an effective alternative to antibiotics,” Dr Venables says.

Anatara’s Chairman, life science industry veteran Mel Bridges, says that growing consumer demand for antibiotic-free food will make Detach™ an attractive product for livestock farmers.

“We have a unique value proposition to enter a market that’s worth billions of dollars every year,” he says.

Anatara Chief Science Officer Dr Tracey Mynott, who was one of the creators of Detach™, says the medicine works against bacteria, viruses and other causes of diarrhoea.

“Detach™ acts by stopping bacteria from attaching to the lining of the intestine, as well as blocking the action of their toxins, the underlying cause of diarrhoea. It works differently to antibiotics in that it doesn’t try to kill bacteria and instead lets them pass through the intestine harmlessly.”

While at the BIO International Convention, Anatara will seek partnering opportunities with animal health companies to distribute Detach™ around the world. It will also seek partners to develop the medicine for human use.